Investor Presentation Q1-Q3 2020

13 Investor presentation First nine months of 2020 Ziltivekimab phase 2b RESCUE trial has successfully completed In the RESCUE trial, zilti QM showed reduction in hsCRP at all dose levels ■placebo ■ziltivekimab 7.5 mg ziltivekimab 15 mg Iziltivikemab 30 mg Zilti QM showed reductions in inflammation biomarkers³ % change¹ 12 weeks of treatment End of treament² 0% Zilti QM appeared to have a safe and well-tolerated profile -3% -5% -20% -40% -60% -80% * -77% -100% -88% * * -92% -79% * -91%* * -93% Addressing the residual risk of CVD for more than 5 million patients with ASCVD, CKD, and inflammation4 Novo Nordisk® The phase 3 cardiovascular outcomes trial is expected to be initiated in H2 2021 1 Primary endpoint was the median percent change in hsCRP, * Indicates statistical significance, p < .0001 2 End of treatment is defined as the average of values at week 23 and week 24 3 Inflammation biomarkers include: Fibrinogen, serum amyloid A, haptoglobin and NTproBNP 4 Inflammation is defined as c-reactive protein levels greater than 2 Zilti: Ziltivekimab; QM: Once-montly; hsCRP: High-sensitivity C-reactive protein; CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; CKD: Chronic kidney disease

View entire presentation